Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target hoisted by Evercore ISI from $33.00 to $45.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently ...

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target boosted by Scotiabank from $27.00 to $32.00 in a research report released on Wednesday,Benzinga reports. Scotiabank currently has ...

We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Travere Therapeutics, Inc. (NASDAQ:TVTX) stands against other ...

Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial ...

Calvin Sandra, the Senior Vice President and Chief Accounting Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), executed a ...

Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), a $2 billion market cap biopharmaceutical company whose stock has surged 190% over the past year, recently sold 2,568 shares of the company's ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 115, ...